31P-magnetic resonance spectroscopy (31P-MRS) detects early  changes in kidney high-energy phosphate metabolism  during a 6-month Valsartan treatment in diabetic  and non-diabetic kidney-transplanted patients.
(31)P-magnetic resonance spectroscopy ((31)P-MRS) is a non-invasive tool to study high-energy phosphate (HEP) metabolism. We evaluate whether 31P-MRS can detect early changes in kidney HEP metabolism during a 6-month trial with Valsartan. Twenty consecutive stable and normotensive kidney-transplanted patients were enrolled. Nine of them received short-term low-dose Valsartan treatment (80 mg/day) for 6 months, while 11 controls received no medication. Kidney HEP metabolism was evaluated both at baseline and after treatment by (31)P-MRS with a 1.5 T system (Gyroscan Intera Master 1.5 MR System; Philips Medical Systems, Best, The Netherlands). Valsartan-treated patients (n = 9) showed a significant increase in β-ATP/Pi ratio, a marker of kidney HEP metabolism (baseline = 1.03 ± 0.08 vs. 6 months = 1.26 ± 0.07, p = 0.03). In contrast, the b-ATP/Pi ratio in the control group (n = 11) did not change (baseline = 0.85 ± 0.10 vs. 6 months = 0.89 ± 0.08, ns). The improvement in the β-ATP/Pi ratio was not associated with a reduction in arterial blood pressure or in urinary albumin excretion. Kidney-localized (31)P-MRS can detect early changes in kidney HEP metabolism during a short-term low-dose Valsartan treatment in stable normotensive kidney-transplanted patients.
Nephrology Division, Transplantation Research Center, Children’s Hospital, Brigham and Women's Hospital, Harvard Medical School, 300 Longwood Avenue, Enders Building, EN530, Boston, MA, USA. paolo.fiorina@childrens.harvard.edu
Paolo
P
Fiorina
Roberto
R
Bassi
Chiara
C
Gremizzi
Andrea
A
Vergani
Rossana
R
Caldara
Alessandra
A
Mello
Alessandro
A
Del Maschio
Francesco
F
De Cobelli
Gianluca
G
Perseghin
Antonio
A
Secchi
D000328:Adult; D057911:Angiotensin Receptor Antagonists / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007668:Kidney / Q000737:chemistry / Q000187:drug effects* / Q000378:metabolism*; D007676:Kidney Failure, Chronic / Q000628:therapy; D016030:Kidney Transplantation; D009682:Magnetic Resonance Spectroscopy / Q000379:methods*; D008297:Male; D008875:Middle Aged; D010710:Phosphates / Q000378:metabolism*; D013777:Tetrazoles / Q000627:therapeutic use*; D014633:Valine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000068756:Valsartan
D057911:Angiotensin Receptor Antagonists; D010710:Phosphates; D013777:Tetrazoles; D000068756:Valsartan; D014633:Valine